Composition for the prevention of infection by SARS-COV-2

Today’s cyclodextrin is interesting both from the application and the formulation point of view. Mouth rinses and mouthwashes are not so common with CDs, yet certainly they are gainly space in dental hygiene. Yet in this invention from MAGI Euregio, not only the comlex forming, but also antiviral (specifically anti covid) properties are also exploited.

The composition includes α-cyclodextrin and hydroxytyrosol and is effective (even proven clinically) in preventing SARS-CoV-2 infection, whereas also effective in contrasting halitosis in subjects that wear a mask for a prolonged period.

Espacenet – Composition for the prevention of infection by SARS-COV-2

What are GLP-1s?

GLP-1-based therapies, such as GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors, improve glucose control through various mechanisms including increased insulin secretion, slower gastric emptying, and reduced postprandial glucagon and food intake. These therapies do not typically cause hypoglycemia on their own but may occur when used in combination with additional glycemic drugs. Apart from GLP-1 therapies reducing glucose levels (HbA1c) they also offer additional benefits which will influence the prescriber in finding the correct drug for a specific patient outcome. Dulaglutide, liraglutide and subcutaneous semaglutide have been approved for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus with established cardiovascular disease, dulaglutide is approved for use in type 2 diabetes mellitus with multiple risk factors, and both liraglutide and semaglutide have been approved for chronic weight management.

Drug shortages of long-acting GLP-1 receptor agonists and dual GLP-1/GIP receptor agonist have emerged unexpectedly and persisted through the first quarter of 2023. This occurred due to an unexpected increase in demand without adequate adjustment in production. The shortage has created new access barriers for patients previously using or wishing to initiate these products for glycemic management, weight loss, and/or cardiovascular risk reduction.

FDA-Approved Alzheimer’s Medications

⚫ Alzheimer’s disease takes a toll on not just the people suffering from the disease but also on their loved ones and caregivers in a way that almost no other illness does.

⚫ The Alzheimer’s disease market is projected to experience robust growth at a compound annual growth rate of 20% from $2.2 billion in 2020 to $13.7 billion in 2030!

🔶 Drug Development Pipeline:
🔸 187 current trials assessing 141 unique drugs
🔸 Phase 3: 36 drugs
🔸 Phase 2: 87 drugs
🔸 Phase 1: 31 drugs

🔷 Phase 3 has 36 agents in 55 trials:
🔹 DMT*-Biologics: 9 (25%)
🔹 DMT*-Small molecules: 15 (42%)
🔹 Putative cognitive-enhancers: 5 (14%)
🔹 Neuropsychiatric symptoms: 7 (19%)
*DMT stands for disease-modifying therapies

🔶 Most Common Targets:
🔸 Transmitter receptors, amyloid, synaptic function, and inflammation

🔷 58 new drugs have entered the pipeline in the past year!
🔷 28% of candidate therapies are repurposed from other diseases!

⚫Despite the hype, controversy, and occasional scandal surrounding the approval of Alzheimer’s drugs, and the disappointing reports of the ineffectiveness of recently approved drugs, many companies are still dedicating time and resources to finding a potential cure for this debilitating disease. This gives hope that the future is bright for those living with Alzheimer’s.

🔶 Learn more:
🔸 Alzheimer’s disease drug development pipeline: 2023 – Cummings – 2023 – Alzheimer’s & Dementia: Translational Research & Clinical Interventions – Wiley Online Library
🔸 Alzheimer’s Drug Market To Hit $13B As FDA Approvals And Insurance Coverage Escalate (

Great collection from Maryam Daneshpour

Differences in the Intracellular Localization of Methylated β-Cyclodextrins-Threaded Polyrotaxanes Lead to Different Cellular States

Today’s cyclodextrin is an essential paper on understanding differences in internalization and cellular location of various polyrotaxanes by Hokkaido UniversityJapan Science and Technology Agency (JST) and Tokyo Medical and Dental University

Activation of autophagy represents a potential therapeutic strategy for the treatment of diseases that are caused by the accumulation of defective proteins and the formation of abnormal organelles. Methylated β-cyclodextrins-threaded polyrotaxane (Me-PRX), a supramolecular structured polymer, induces autophagy by interacting with the endoplasmic reticulum. The same level of autophagy induction was achieved at one-twentieth the dosage for the mitochondria-targeted nanocarrier (Me-PRX) compared to the naked Me-PRX. The quantitative evaluation of the intracellular organelle localization of both naked Me-PRX and the MITO-Porter (Me-PRX) are reported here. Mitochondria, endoplasmic reticulum and lysosomes were selected as target organelles because they would be involved in autophagy induction. In addition, organelle injury and cell viability assays were performed. The results showed that the naked Me-PRX and the MITO-Porter (Me-PRX) were localized in different intracellular organelles, and organelle injury was different, depending on the route of administration, indicating that different organelles contribute to autophagy induction. These findings indicate that the organelle to which the autophagy-inducing molecules are delivered plays an important role in the level of induction of autophagy.

Biomolecules | Free Full-Text | Differences in the Intracellular Localization of Methylated β-Cyclodextrins-Threaded Polyrotaxanes Lead to Different Cellular States (

Preparation process of low-irritation hair dye with color protection function

Today’s cyclodextrin:
With the party mood of the weekend approaching, let’s see an example of using CDs as hair dye components. The invention provides a low-irritation hair dye with a color protection function. As claimed, the hair dye can greatly reduce scalp irritation, reduce scalp stabbing pain and burning feelings caused by hair dyeing of consumers in the past, reduce direct contact between irritant substances and scalp, and greatly reduce scalp irritation.

Espacenet – Preparation process of low-irritation hair dye with color protection function